OPERA-01
43 evidence topics · 11 sources
Objective
Trial objective
“OPERA-01 (NCT06016738) is a phase III study designed to evaluate the safety and efficacy of palazestrant monotherapy compared to SOC ET in patients with ER+, HER2– locally advanced or metastatic breast cancer, regardless of ESR1 mutation status, whose disease advanced following treatment with at least one ET in combination with a CDK4/6i.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Main objectives in the EU trial authorization
Location and study date
Registry dates
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2023-11-16” |
| Primary completion (estimated) | “2026-10-31” |
| Study completion (estimated) | “2028-02-29” |
Registration and start of enrollment
“Clinical Trial Registration: Clinicaltrials.gov NCT06016738. Registered 17 August 2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Enrollment began in November 2023.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Enrollment completion and expected top-line results
Study design
Randomized, open-label, two-part design
“The OPERA-01 study is a global phase III randomized, open-label, active-controlled study, consisting of two parts (Figure 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Part 2, participants are randomized at a 1:1 ratio to receive once‑daily oral palazestrant (90 mg QD) or the investigator’s choice of SOC ET.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Part 1 dose selection
“In Part 1, the dose-selection portion of the study, eligible participants were randomized 1:1:1 to receive oral palazestrant at a dose of 90 mg or 120 mg once daily (QD) or investigator’s choice of SOC ET” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Independent Data Monitoring Committee recommended a 90-mg palazestrant QD dose based on the available safety, efficacy, patient-reported outcomes, and pharmacokinetic data from participants treated in Part 1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prespecified criteria for selecting the Part 2 dose
Stratified randomization
“Participants (N = 510 overall and 470 in the primary analysis) are randomized to treatment arms using Interactive Response Technology, and randomization is stratified based on 1) the presence of ESR1-mut or absence of detectable ESR1 mutations (ESR1-mut-nd), assessed centrally on circulating tumor DNA (ctDNA) collected during screening period in line with NCCN Guidelines [16]; 2) prior lines of ET for advanced disease (1 vs 2); and 3) presence of visceral disease (yes vs no).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Independent data monitoring committee
Eligibility criteria
Population
“Male and female participants aged 18 years or older are eligible for enrollment in the OPERA-01 study if they have a confirmed diagnosis of inoperable locally advanced or metastatic ER+, HER2– breast cancer that is not amenable to curative treatment. Participants must have progressed following treatment with the combination of ET and a CDK4/6i; one additional line of ET is allowed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key inclusion criteria
Receptor status definitions
“Laboratory-confirmed ER+, HER2– breast cancer (per ASCO-CAP guidelines)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“0 or 1+ by IHC for HER2 membrane protein” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Key exclusion criteria
Prior antibody-drug conjugates and washout periods
“Prior chemotherapy (including ADC) in the advanced/metastatic setting” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Fulvestrant, <28 days prior” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ET, CDK4/6i, everolimus, tacrolimus, alpelisib, or PARP inhibitors, <14 days prior” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Palazestrant and comparator regimens
“In Part 2, participants receive once-daily palazestrant (90 mg QD) or SOC ET as described in Part 1. Fulvestrant or the AIs letrozole, anastrozole, or exemestane (with gonadal suppression in pre- and perimenopausal women or men) are included as the physician’s choice of SOC ET monotherapy for the control arm.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment cycles and duration
“All treatments are administered in 28-day cycles and continue until confirmed radiographic disease progression, intolerable toxicity, continuous dose-interruption >28 days, investigator or participant decision, or initiation of a non-protocol anti-cancer therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for the endocrine monotherapy control arm
“The SOC ET in the control arm aligns with the NCCN and ASCO guidelines recommending ET monotherapy as a treatment option to delay chemotherapy, supported by evidence demonstrating sustained endocrine sensitivity and responsiveness of ER+, HER2− breast cancer to fulvestrant, tamoxifen, or non-steroidal AIs ET, even after prior ET failures [16–18,45–51]. As a global study, the SOC control arm has been planned to account for regional variations in standard practices.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using progression-free survival by blinded independent central review as the primary endpoint
Dual primary endpoint
“The dual primary endpoint of the overall study is blinded independent committee review (BICR)-assessed PFS, defined as the time from randomization to the date of the first documented progression or death due to any cause, in participants with ESR1-mut and ESR1-mut-nd tumors, to be assessed separately.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for separate analyses by ESR1 mutation status
“However, recent reports indicate that the clinical benefit in ER+, HER2– ABC may be limited to patients with ESR1-mutated (ESR1-mut) tumors, rather than the entire patient population: trials investigating the efficacy of the PROteolysis Targeting Chimera ER degrader (PROTAC), vepdegestrant, and the SERD, imlunestrant, showed progression-free survival (PFS) benefits specific to patients harboring ESR1 mutations [28,29].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Regulatory rationale for progression-free survival
Secondary endpoints
“Key secondary endpoints of overall survival (OS), defined as the time from randomization to the date of death due to any cause regardless of whether the patient withdraws from randomized therapy or receives another subsequent anti-cancer therapy, will be assessed separately in participants with ESR1-mut and ESR1-mut-nd tumors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“BICR-assessed PFS in the ITT population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PROs (assessed using EQ-5D-5 L and EORTC QLQ-C30)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tumor and safety assessments
“Adverse event (AE) severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Tumor response and disease progression are assessed locally and centrally using body imaging by computed tomography (preferred) or magnetic resonance imaging. Baseline tumor imaging is performed during screening, within 28 days of randomization, and radiographic assessments are conducted periodically.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment: registry record
| Enrollment type | Participants |
|---|---|
| Estimated | “510” |
Participants randomized in Part 1 and planned for the primary comparison
Planned participants per arm
| Part and arm | Planned participants |
|---|---|
| Total | “n = 510” |
| Part 1, each arm (palazestrant 90 mg, palazestrant 120 mg, standard-of-care endocrine therapy) | “n = 40” |
| Part 2, each arm (palazestrant 90 mg, standard-of-care endocrine therapy) | “n = 195 (total 235)” |
Description of analysis sets
Primary and key secondary analyses
“Blinded independent committee review (BICR)-assessed PFS, locally assessed PFS, and overall survival (OS) will be analyzed separately in participants with ESR1-mut tumors and participants with ESR1-mut-nd tumors by Kaplan–Meier (KM) methods; median and 95% confidence intervals (CIs) will be reported. Significant differences between treatment groups will be analyzed using the stratified log-rank test, stratified by a number of prior lines of ET and presence or absence of visceral metastases. Cox regression models will be used to estimate hazard ratios and 95% CIs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Part 1 dose-selection analysis
“In Part 1 of the study, the selected dose was based on analyses of safety, preliminary efficacy, PK/pharmacodynamic (PD) parameters, and other relevant clinical and laboratory data, and there was no formal statistical comparison.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
No efficacy or safety results from OPERA-01 have been reported; enrollment is complete, and top-line results are anticipated in the first quarter of 2027. The trial is open label, with PFS assessed by blinded independent central review as the dual primary endpoint. The 90 mg Part 2 dose was chosen from Part 1 data with no formal statistical comparison. The control arm is endocrine monotherapy (fulvestrant or an aromatase inhibitor), and fulvestrant was recommended to participants who had not previously received it. Eligibility excludes participants with prior chemotherapy in the advanced or metastatic setting, prior elacestrant, or symptomatic visceral disease, permits at most one additional line of endocrine therapy after the endocrine therapy and CDK4/6 inhibitor combination, and requires the most recent endocrine therapy to have lasted at least 6 months. Participants receive a tablet formulation, whereas the earlier monotherapy data were obtained with capsules. The trial design publication was funded by Olema Oncology, which was involved in the study design.
Fulvestrant recommended only for participants without prior fulvestrant
“Fulvestrant was recommended to patients who have not previously received fulvestrant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The inclusion of AI monotherapy ensures consistency with guideline-supported treatment options across diverse clinical settings [16–18,49].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote